PCI and CABG in patients with triple vessel disease: reflections in the aftermath of SYNTAX II and FAME III

Dr Dejan Milasinovic is an interventional cardiologist at the Department of Cardiology, Clinical Center of Serbia. He is also an Assistant Professor at Faculty of Medicine, University of Belgrade. His main research interests focus in the fields of the invasive treatment of acute coronary syndromes and complex coronary interventions, with an emphasis on bifurcation PCI and intracoronary guidance. In 2016, Dr Milasinovic received the EuroPCR 2016 Best Abstract award, for a work on the timing of invasive coronary intervention in patients with non-ST-segment elevation myocardial infarction. He is a member of European Association of Percutaneous Cardiovascular Interventions (EAPCI) and has served as program committee member of the annual EuroPCR conference. Dr Milasinovic also serves on the editorial boards of EuroIntervention (editorial consultant) and PCRonline and is the Chair of the EAPCI Young committee.

Prof Javier Escaned is Head of Section (Interventional Cardiology Section) at Hospital Clinico San Carlos / Complutense University (Madrid, Spain). He trained in the United Kingdom as Specialist in Cardiology and obtained his PhD in The Netherlands. Author of >700 indexed scientific articles on interventional cardiology, imaging and physiology (h-index 100) and over 30 years of experience as PCI operator, he regularly lectures and performs live cases at major scientific and educational meetings. He is a recipient of the European Society of Cardiology (ESC) Silver Medal and the Andreas Grüntzig Award for his contributions to the fiedl fo Interventional Cardiology. Main areas of expertise include complex PCI, intracoronary diagnostics and functional coronary angiography. His track record in coronary physiology comprises being investigator on pioneer FFR trials like DEFER (1998), collaborator with Justin Davies in the validation and clinical implementation of iFR, and developer of new tools for the assessment of coronary microcirculation. Editorial roles include Deputy Editor EHJ, Advisory Editor Eurointervention, editor of the textbooks “Coronary Stenosis: Imaging, Structure and Physiology” and “Physiological Assessment of Coronary Stenoses and the Microcirculation". Recent board positions include EAPCI board / Education Committee Chair, ESC WG Coronary Pathophysiology and Microcirculation, EuroCTO Board. Recent trials as Principal Investigator include ADVISE II, DEFINE FLAIR, SYNTAX II, PIONEER IV, Cerebral-Coronary-Connection (C3), DCR4Contrast, INOCA LongCovid and AID ANGIO. Additional interests are philosophy and music.

Dr Justin Davies is a board member of Monaco Cardio at the Princess Grace Hospital, Monaco, and an interventional cardiologist with over 15 years of experience as a leading educator in the field. His clinical and academic career was established at Hammersmith Hospital, Imperial College London, where he built an international reputation for innovation in cardiovascular medicine. Over the course of his career, he has successfully mentored 15 PhD students, published more than 500 peer-reviewed papers — including landmark studies in the New England Journal of Medicine and The Lancet — and holds 20 patents in cardiovascular medicine and technology. He was the co-principal investigator of the DEFINE-FLAIR study, which helped establish iFR (Instantaneous Wave-Free Ratio), a diagnostic technique he invented, as a globally adopted standard in coronary physiology. His work reflects a unique blend of scientific innovation, academic leadership, and clinical excellence. In addition to his research and academic commitments, Justin is CEO of Cerebria AI, where he leads the development of next-generation AI-powered cardiovascular imaging and physiology tools. Under his leadership, Cerebria AI is advancing cutting-edge solutions that integrate artificial intelligence with frontline cardiology to enhance clinical decision-making and patient outcomes. Combining deep clinical expertise with entrepreneurial vision, he continues to guide international ventures through funding, regulatory pathways, and commercialization, while remaining committed to transforming cardiovascular care on a global scale.

Prof Patrick W. Serruys with respected h-index – 183 is a professor of Interventional Cardiology at the Interuniversity Cardiological Institute of the Netherlands (1988-1998) and Erasmus MC. Since 1980 he was a Director of the Clinical Research Program of the Catheterization Laboratory, Thorax Center at Erasmus University, and till April 1, 2014 (retirement date) the Head of the Interventional Department, Thorax Center, Erasmus MC (University Medical Center Rotterdam), Rotterdam, The Netherlands. Since April 2013, he holds the position of Professor of Cardiology in the Cardiovascular Science Division of the National Heart and Lung Institute (NHLI) at the Faculty of Medicine, within the Imperial College of Science, Technology and Medicine, London.He is a Fellow of the American College of Cardiology and a Fellow of the European Society of Cardiology and scientific council of the International College of Angiology.In 1996, he received the TCT Career Achievement Award and in 1997 he was awarded the Wenkebach Prize of the Dutch Heart Foundation. In 2000, he was awarded the Gruentzig Award of the European Society of Cardiology. In 2001, he held the Paul Dudley White Lecture at the American Heart Association in the USA. In 2004, he received the Andreas Gruentzig Award of the Swiss Society of Cardiology. In 2005, he held the 4th International Lecture at the AHA and Mikamo Lecture at the Japanese heart Association. In 2006, he received the highest award of the Clinical Council of the American Heart Association: the James Herrick Award. In 2007, he received the Arrigo Recordati International Prize (Italy) and the ICI Achievement Award (bestowed by the President of Israel – Shimon Perez). In 2008, he received the Einthoven Penning (Leiden). In 2009, he became Doctor Honoris Causa from the University of Athens. In 2011, he received the Lifetime Achievement Award, bestowed by the American College of Cardiology, in recognition of many years of service and invaluable contributions to the ACC. At the end of 2011, Prof Serruys received the Ray C. Fish Award, bestowed by the Texas Heart Institute, for outstanding achievement and contribution to cardiovascular medicine. In 2012, he received a Golden Medal of the European Society of Cardiology. In 2013, he became Doctor Honoris Causa from the Complutense University of Madrid. In 2016, he became Doctor Honoris Causa of the Melbourne University, Australia. Currently he is established Professor of Interventional Medicine and Innovation at the National University of Ireland, Galway.